Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 2/20 | 0.58 |
| ▸ | THRB | P10828 | 1/20 | 0.58 |
| ▸ | PDE7A | Q13946 | 8/20 | 0.57 |
| ▸ | TDP1 | Q9NUW8 | 5/20 | 0.54 |
| ▸ | MEN1 | O00255 | 2/20 | 0.54 |
| ▸ | MAPT | P10636 | 2/20 | 0.54 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.54 |
| ▸ | GFER | P55789 | 1/20 | 0.54 |
| ▸ | ATM | Q13315 | 1/20 | 0.54 |
| ▸ | PDE7B | Q9NP56 | 2/20 | 0.47 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.47 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 3/20 | 0.46 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.46 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.46 |
| ▸ | TXNRD1 | Q16881 | 1/20 | 0.46 |
| ▸ | TXNRD3 | Q86VQ6 | 1/20 | 0.46 |
| ▸ | TXNRD2 | Q9NNW7 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 1/20 | 0.46 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL11707930 | 0.85 | PDE7A (0.57) | GAATHRBPDE7ATDP1MEN1 | |
| Hydrochloric Acid SCHEMBL11709322 | 0.84 | PDE7A (0.56) | GAATHRBPDE7ATDP1MEN1 | |
| SCHEMBL6927792 | 0.79 | ERN1 (0.56) | GAATHRBPDE7AMEN1MAPT | |
| SCHEMBL1454650 | 0.78 | NR1H2 (0.52) | GAATHRBPDE7ATDP1MEN1 | |
| SCHEMBL177714 | 0.78 | MAPT (0.66) | GAATHRBTDP1MEN1MAPT | |
| SCHEMBL810480 | 0.77 | CTSV (0.49) | PDE7AMEN1MAPTKMT2AALDH1A1 | |
| SCHEMBL8781019 | 0.77 | KMT2A (0.65) | GAATHRBPDE7AMEN1MAPT | |
| SCHEMBL9805799 | 0.77 | GAA (0.63) | GAATHRBPDE7ATDP1MEN1 | |
| SCHEMBL810614 | 0.76 | PDE7A (0.65) | PDE7ATDP1MEN1MAPTKMT2A | |
| SCHEMBL6935214 | 0.75 | GAA (0.46) | GAAPDE7AMEN1MAPTKMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1971611-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-10-10 | — | — | EP | disclosed |
| CN-102702193-A | Anti-viral compounds | ABBOTT LAB | 2012-10-03 | — | — | CN | disclosed |
| US-8236950-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2012-08-07 | — | — | US | disclosed |
| EP-1979348-B1 | ANTI-VIRAL COMPOUNDS | ABBOTT LAB (US) | 2012-01-18 | — | — | EP | disclosed |
| EP-2345652-A1 | Antiviral compounds | Abbott Laboratories (US) | 2011-07-20 | — | — | EP | disclosed |
| US-20110160233-A1 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2011-06-30 | — | — | US | disclosed |
| US-7915411-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-29 | — | — | US | disclosed |
| US-7910595-B2 | Anti-viral compounds | ABBOTT LABORATORIES (US) | 2011-03-22 | — | — | US | disclosed |
| EP-2094276-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2009-09-02 | — | — | EP | disclosed |
| CN-101443334-A | Anti-viral compounds | ABBOTT LAB (US) | 2009-05-27 | — | — | CN | disclosed |
| CN-101384591-A | Antiviral compounds | ABBOTT LAB (US) | 2009-03-11 | — | — | CN | disclosed |
| WO-2008133753-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2008-11-06 | — | — | WO | disclosed |
| EP-1979348-A2 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-10-15 | — | — | EP | disclosed |
| EP-1971611-A1 | ANTI-VIRAL COMPOUNDS | Abbott Laboratories (US) | 2008-09-24 | — | — | EP | disclosed |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-10-04 | — | — | US | disclosed |
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | ABBVIE INC. | 2007-08-23 | — | — | US | disclosed |
| WO-2007081517-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-19 | — | — | WO | disclosed |
| WO-2007076034-A2 | ANTI-VIRAL COMPOUNDS | ABBOTT LABORATORIES (US) | 2007-07-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110160233-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | GAA 504/4885THRB 4833/4885PDE7A 4223/4885 |
| US-20070197558-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | GAA 504/4885THRB 4833/4885PDE7A 4223/4885 |
| US-20070232627-A1 | ANTI-VIRAL COMPOUNDS | HAVCR2, MAVS, EIF2AK2 | GAA 504/4885THRB 4833/4885PDE7A 4223/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.